度洛西汀肠溶胶囊联合振源胶囊治疗躯体形式障碍疗效研究

Study on the efficacy of duloxetine combined with Zhenyuan capsule in the treatment of somatoform disorders

目的:探讨度洛西汀肠溶胶囊联合振源胶囊治疗躯体形式障碍的临床疗效。方法:选择2021年1月—2021年6月收治的躯体形式障碍患者60例,随机分为对照组及观察组,每组30例。观察组采用度洛西汀(40~60 mg/d)联合振源胶囊(1.5 g/d)治疗,对照组仅用度洛西汀肠溶胶囊(40~60 mg/d)治疗,两组均连续治疗6周为1个疗程。记录入组前及治疗2周、4周、6周的症状自评量表(SCL-90)评分、汉密尔顿抑郁量表(HAMD)评分及不良反应,观察并发症发生率及临床效果。结果:治疗2周、4周及6周后,观察组SCL-90评分和HAMD评分均低于对照组,差异有统计学意义(P<0.05);观察组恶心呕吐、头晕头痛及疲乏的发生率低于对照组,差异有统计学意义(P<0.05);观察组总有效率高于对照组,差异有统计学意义(P<0.05)。结论:度洛西汀肠溶胶囊联合振源胶囊用于躯体形式障碍患者,能有效改善患者临床症状,降低抑郁评分,且不良反应少,临床效果可靠。

Objective:To explore the clinical efficacy of duloxetine combined with Zhenyuan capsule in the treatment of somatoform disorders.Methods:Sixty patients with somatoform disorders admitted to our hospital from January 2021 to June 2021 were selected as the research objects.Randomly divided into a control group and observation group with 30 cases each.The observation group was treated with duloxetine(40~60 mg/d)combined with Zhenyuan capsule(1.5 g/d),the control group was treated with duloxetine(40~60 mg/d)only,and both groups were treated continuously 6 weeks is a course of treatment.Record the scores of the Symptom Self-Rating Scale(SCL-90),Hamilton Depression Scale(HAMD),and Adverse Reaction Scale before enrollment,2 weeks,4 weeks,and 6 weeks of treatment,and count the complications and overall Clinical effect.Results:After 2 weeks of treatment,4 weeks of treatment,and 6 weeks of treatment,the SCL-90 scores of the observation group were lower than those of the control group(P<0.05).After 2 weeks of treatment,4 weeks of treatment,and 6 weeks of treatment,the HAMD scores of the observation group were all Lower than the control group(P<0.05),the total proportion of nausea,vomiting,dizziness,headache,and fatigue in the observation group was significantly lower than that in the control group(P<0.05),and the total effective rate in the observation group was higher than that in the control group(P<0.05).Conclusion:For patients with somatoform disorders,the use of duloxetine combined with Zhenyuan Capsules can effectively improve the clinical symptoms of the patients,reduce the depression score,and have fewer adverse reactions and reliable clinical effects.